Successful olaparib desensitization using a novel one-day protocol
| Autor: | Hannah Roberts, Stephen Welch, Rongbo Zhu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
lcsh:Immunologic diseases. Allergy
Oncology medicine.medical_specialty Allergy Drug desensitization medicine.medical_treatment Drug allergy Case Report Olaparib 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Breast cancer Internal medicine medicine Chemotherapy agent In patient 030212 general & internal medicine Desensitization (medicine) business.industry General Medicine medicine.disease chemistry 030220 oncology & carcinogenesis lcsh:RC581-607 business |
| Zdroj: | Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology Allergy, Asthma & Clinical Immunology, Vol 16, Iss 1, Pp 1-3 (2020) |
| ISSN: | 1710-1484 |
| Popis: | Background Olaparib is a revolutionary treatment for patients with ovarian and breast cancer. Currently, there is no established 1-day drug desensitization protocol for patients with olaparib type-1 hypersensitivity reactions despite well documented IgE-mediated adverse reactions occurring with olaparib. Case presentation We report a 58-year-old female with immediate, reproducible IgE-mediated adverse reactions to olaparib tablets with implementation of a 1-day novel desensitization protocol to olaparib. Following desensitization, the patient was successfully transitioned from olaparib capsules to tablets with no loss of tolerance. Conclusions To our knowledge, this is the first reported case of successful olaparib desensitization using a novel 1-day desensitization protocol, and will contribute to drug allergy knowledge, in an area where robust data is lacking. This case demonstrates the important role for drug desensitization in patients with immediate hypersensitivity reactions to chemotherapeutic agents. Furthermore, as olaparib capsules are being phased out in favour of olaparib tablets, we provide a clear case that transitioning from capsule to tablet form did not cause a loss of tolerance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |